AMAG Pharmaceuticals, Inc. (AMAG) Earns Hold Rating from Cantor Fitzgerald
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating reissued by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Monday. They presently have a $23.00 target price on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 25.34% from the company’s current price.
The analysts wrote, “AMAG disclosed that the Makena auto-injector sNDA has been accepted for review and that the FDA set a PDUFA date of February 14, 2018.””
A number of other equities analysts also recently commented on the company. Barclays PLC reiterated an “equal weight” rating and set a $20.00 price objective (down previously from $25.00) on shares of AMAG Pharmaceuticals in a research report on Thursday, June 1st. ValuEngine downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. TheStreet downgraded AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 5th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $34.00 price objective (down previously from $40.00) on shares of AMAG Pharmaceuticals in a research report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. AMAG Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $29.44.
AMAG Pharmaceuticals (NASDAQ AMAG) traded down 2.45% during mid-day trading on Monday, reaching $17.90. The company had a trading volume of 421,079 shares. The stock has a 50 day moving average of $18.26 and a 200 day moving average of $23.88. The stock’s market capitalization is $627.31 million. AMAG Pharmaceuticals has a 52 week low of $16.00 and a 52 week high of $36.83.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a positive return on equity of 1.69% and a negative net margin of 5.61%. The company had revenue of $139.47 million for the quarter, compared to analysts’ expectations of $150.32 million. During the same quarter in the previous year, the business posted ($0.22) EPS. The business’s quarterly revenue was up 27.6% compared to the same quarter last year. Analysts anticipate that AMAG Pharmaceuticals will post $5.09 earnings per share for the current year.
In other AMAG Pharmaceuticals news, SVP Julie Krop sold 1,891 shares of AMAG Pharmaceuticals stock in a transaction on Monday, May 1st. The stock was sold at an average price of $24.45, for a total value of $46,234.95. Following the sale, the senior vice president now owns 36,777 shares in the company, valued at $899,197.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.80% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the stock. Skandinaviska Enskilda Banken AB publ increased its stake in AMAG Pharmaceuticals by 45.6% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 158,600 shares of the specialty pharmaceutical company’s stock worth $3,576,000 after buying an additional 49,700 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in AMAG Pharmaceuticals by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 607,980 shares of the specialty pharmaceutical company’s stock worth $13,710,000 after buying an additional 376,139 shares in the last quarter. Credit Suisse AG increased its stake in AMAG Pharmaceuticals by 122.3% in the first quarter. Credit Suisse AG now owns 145,442 shares of the specialty pharmaceutical company’s stock worth $3,280,000 after buying an additional 80,011 shares in the last quarter. Tudor Investment Corp ET AL increased its stake in AMAG Pharmaceuticals by 99.1% in the first quarter. Tudor Investment Corp ET AL now owns 22,300 shares of the specialty pharmaceutical company’s stock worth $503,000 after buying an additional 11,100 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in AMAG Pharmaceuticals during the first quarter worth approximately $403,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.